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2016 Annual Report

Dear friends and colleagues,
Last year, we shared the inspiring news that IPM’s monthly dapivirine ring helps to safely reduce a woman’s risk of HIV infection. We were encouraged by the enthusiasm of many women who participated in The Ring Study when they heard the primary results, which was so nicely summed
up by one participant: “I wish that the ring can be approved and be available to all women who are sexually active and want to use it to protect
themselves against HIV.”
As we learned more about the ring’s potential from additional analyses, we heard similar expressions of enthusiasm from women and partners
around the world. Bolstered by this global commitment to addressing women’s urgent HIV prevention needs with innovative technologies, we are
optimistic that the ring results mark an important milestone on the road to offering women an effective long-acting prevention method.
The dapivirine ring can serve as an example of what the product development partnership (PDP) model can achieve. Yet our work is far from done.
For IPM, the “D” in PDP stands for development and delivery. IPM is providing the ring to former Phase III trial participants as well as young women
using the ring for the first time through open-label studies that may help us better understand adherence challenges and ways to address them. IPM
is submitting the first applications this year and in 2018 for the ring’s regulatory approval — a critical next step toward expanding women’s options.
As IPM works to make an affordable dapivirine ring available to women, we remain just as focused on developing a pipeline of next-generation
products to stay ahead of the virus, including a three-month dapivirine ring, a three-month ring that combines dapivirine with a contraceptive, and
three-month rings that combine multiple ARVs.
There is a saying that sticks in a bundle are unbreakable. Indeed, our work is only possible with continued — and even more focused — collaboration on a variety of fronts across countries and sectors, from supporting uptake and use of effective prevention methods to integrating new options
into health systems and financing their affordable access. We are enormously grateful to our donors and partners, who, like us, believe that women
deserve HIV prevention options that meet their needs, including oral PrEP and rings as well as next-generation methods being developed. In 2016,
our hope was renewed that such a future is indeed possible.

		
Dr. Zeda F. Rosenberg 		

		

Founder and Chief Executive Officer			

Dr. James McIntyre
Chair of the Board

HIV/AIDS remains the leading cause of death among women ages 15-44,
with nearly one million women and girls newly infected worldwide in
2015. In sub-Saharan Africa, where the epidemic has taken its greatest
toll, nearly 60 percent of new infections among adults ages 15 and older
are in women.
These stark statistics — which represent millions of women’s lives —
drive our work to develop and deliver new HIV prevention approaches for
women, for whom existing methods are not doing enough to reduce their
risk of infection. Women urgently need solutions that meet their needs,
which can change throughout their lives.
In 2016, IPM made promising strides toward fulfilling its founding
mission to provide women with products they could use themselves to
prevent HIV. We look back at milestones from 2016 — and the next steps
to come — that could help usher in a new era: one where women have
the range of options they need to stay healthy and HIV-free.
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MILE
STONE

Dapivirine ring becomes
the first microbicide to show
efficacy in two Phase III trials

In early 2016, IPM’s monthly dapivirine ring was found to safely help reduce HIV
risk in two Phase III trials — making it the first microbicide and the first long-acting prevention product to confirm efficacy.

Building the HIV prevention evidence base
IPM and MTN published primary Ring Study and ASPIRE results, respectively, in the
New England Journal of Medicine, and jointly announced the findings at a press confer-

Dapivirine ring:
At-a-glance
•
•
•
•

Vaginal ring made from flexible silicone
Slowly releases ARV drug dapivirine
Self-inserted monthly
Assessed for safety and efficacy in The
Ring Study, led by IPM, and ASPIRE, led by
the US National Institutes of Health-funded
Microbicide Trials Network (MTN)

ence and sessions at the 2016 Conference on Retroviruses and Opportunistic Infections
in Boston. IPM presented on dapivirine ring research at major scientific conferences
throughout the year, including the 2016 International AIDS Conference (AIDS 2016) in
Durban and the 2016 HIV Research for Prevention (R4P) Conference in Chicago.

The ring was found to safely reduce infection among more than 4,500 women in
Malawi, South Africa, Uganda and Zimbabwe by approximately 30 percent overall.
Additional analyses showed that HIV risk reduction was greater among women who
used the ring consistently.
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SPREADING

THE WORD

To increase public awareness of the dapivirine ring results and the role the ring could play in
broadening the toolkit for women’s HIV prevention, IPM conducted briefings for stakeholders
across Africa, Europe and North America, and hosted events at the Women Deliver conference
in Copenhagen and the United Nations High-level Meeting on HIV and AIDS in New York.
IPM was also a sponsor of the inaugural Women Now!
conference to elevate women’s sexual and
reproductive health and rights and justice issues
in the lead-up to AIDS 2016.
IPM and MTN gathered Phase III participants, trial communities and civil society advocates to share the results and our plans for open-label follow-on studies now ongoing
in the four Phase III countries.
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POTENTIAL ACCESS
REGULATORY PATHWAY
Applications for regulatory
approval to be submitted
starting mid-2017

PAT H WAY S T O A C C E S S F O R T H E R I N G
PUBLIC HEALTH PATHWAY
Open-label studies to provide the
ring to women of reproductive
age, support consistent use and
collect additional safety data

MILE
STONE

Launch of first open-label studies
for an HIV prevention ring

The first open-label studies of a vaginal ring shown to reduce HIV transmission began in July 2016. The two studies, DREAM and HOPE, are providing the dapivirine
ring to former Ring Study and ASPIRE participants, respectively. The data collected
will help us understand how women use the ring now that they know its safety
and efficacy.
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Taking place at six former Ring Study locations in South Africa and Uganda,
IPM’s DREAM study is exploring the feasibility of a three-monthly follow-up
schedule where women visit the clinic to receive a new ring and take two
new rings to insert at home. Similarly designed, MTN’s HOPE study is implementing a three-monthly schedule among an expected 1,500 to 2,000 women
at 15 former ASPIRE sites in Malawi, South Africa, Uganda and Zimbabwe.
IPM’s DREAM study recently expanded enrollment to include 600 young women
ages 18-25 who have not previously used the ring. Given that 4,500 young women in
Africa are newly infected every week, this expansion will provide crucial insights into
how young women might incorporate the dapivirine ring into their lives and will help
inform adherence support strategies. In all, DREAM is expected to enroll about 1,700

Both studies will collect data on why some participants choose not to use
the ring, and HOPE will also explore alternative markers of adherence.
Building on the foundation laid by the Phase III trials, community briefings,
information sessions and sporting events will continue to play an important
role in engaging women and trial communities in both open-label studies.

participants.
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“I feel very protected and more relaxed with the ring
with medication in it. That makes my sex life more
interesting. I am very happy to be in the DREAM study.”
– DREAM participant

In addition, to better understand HIV prevention product preferences and adherence challenges among adolescent girls and young women, IPM is partnering with
MTN to conduct a new study called REACH. To begin in 2017, the study will assess
the safety of and adherence to the monthly dapivirine ring and daily oral pre-exposure prophylaxis (PrEP) among 300 young African women ages 16-21. This
important study will support platforms for conversations about young women’s lives
and HIV prevention needs.
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MILE
STONE

Preparing the first regulatory
applications for an
HIV prevention ring

A peek into the regulatory process
Applying for approval of a new drug like dapivirine involves careful planning and an enormously
synchronized effort. Vice President for Regulatory
Affairs Patricia Mayer offers some insights into

As the regulatory sponsor for the dapivirine ring, IPM is pursuing regulatory approval for

IPM’s approach:

the ring’s use in countries where women are at high risk of HIV infection. If approved, the
ring would be the first microbicide and first vaginal ring licensed for HIV prevention.

Over the past decade, IPM has generated a
tremendous amount of data on the dapivirine

In 2016, IPM continued the intensive process of assembling a dossier containing all data

ring, from early work to optimize the formula-

on the dapivirine ring for its first regulatory reviews.
IPM plans to submit first to the European Medicines Agency (EMA) through Article 58, a
mechanism that provides scientific opinions on products that will be marketed outside of
the European Union in low- and middle-income countries, in consultation with the World
Health Organization (WHO). A positive opinion from the EMA under Article 58 would help
facilitate the ring’s WHO prequalification, which many African regulatory authorities rely on for their own reviews and approvals. IPM also
plans to submit applications to the South African Medicines Control
Council (MCC) in late 2017, and to the US Food and Drug Administration (FDA) in 2018. First approvals in Africa could come
as soon as early 2019.

tion and nonclinical testing to clinical safety and
efficacy. After comprehensive data analyses are conducted, they are compiled
into a dossier according to each regulatory agency’s specific application format.
The process of assembling the dossier started last year, and is an “all hands
on deck” operation as we near our target submission date following a series of
meetings with European regulators to ensure we submit as comprehensive a
package as possible. After we submit the EMA application, we will immediately
start assembling the country-specific applications to the MCC, FDA and each
targeted African country.
Only with a committed team will we be able to reach our goal to potentially offer
women this promising tool as soon as possible.

IPM meets with African national
regulatory authorities from
Ghana, Kenya, Malawi, South
Africa, Uganda, Zambia and
Zimbabwe in 2016 in Cape Town.
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MILE
STONE

Partnering for potential
rollout of the first
HIV prevention ring

PARTNERING
FOR ACCESS

Policymakers and
Government Agencies

The dapivirine ring could add an important component to a future prevention toolkit

Procurement and
Supply Chain

as a long-acting and self-initiated option for women. Leveraging the partnerships
that helped advance the ring through Phase III trials, IPM is collaborating across
public, private and civil society sectors to increase widespread awareness, and to
encourage demand and uptake if the ring is approved and incorporated into HIV

HIV and SRH
Prevention Programs

Donors

prevention strategies.
IPM works with both governmental and traditional

Women, End-Users,
Communities

Civil Society
and Advocates

leaders in South Africa and Uganda to ensure that
discussions on national HIV prevention policies
include the dapivirine ring as an important
potential option for women. National strategic

Health Care Workers
and Clinics

Industry

plans continue to support microbicide research
and eventual introduction.

Implementing
Organizations

Regulatory
Authorities
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IPM expanded its partnership with Janssen Sciences Ireland UC, one of the Johnson & Johnson Pharmaceutical Companies, which granted IPM exclusive worldwide
rights to dapivirine. Janssen committed to a multi-year secondment of a staff member whose commercial marketing expertise will help guide IPM’s market introduction
activities for the dapivirine ring.

Activities in 2016 included:
• Purchasing the new inspection and

Courtesy of 3P Innovation Ltd.

• Exploring how human-centered design

packaging equipment needed to meet

approaches could encourage dapivir-

the manufacturing scale for the ring’s

ine ring uptake and adherence among

potential launch. IPM worked with its

young African women, in partnership

ring manufacturing partner, QPharma

with Dalberg’s Design Impact Group

(Sweden), to install and prepare the

and USAID’s Center for Accelerating

equipment for process validation in

Innovation and Impact.

“Innovation can help rewrite the script for
girls and young women affected by HIV.”
– Jaak Peeters, global head, Global Public Health, Johnson & Johnson

2017 to ensure the ring’s quality.
• Partnering with USAID’s OPTIONS
• Building a brand identity for the ring by

project to advocate for the ring’s inclu-

conducting market research on potential

sion in WHO guidelines and policies,

brand names for the ring among health

and to develop an investment case for

professionals in the US and Africa, and

policymakers and global donors that

preparing for focus group discussions

demonstrates the ring’s potential public

with potential end-users in 2017. IPM

health impact and cost-effectiveness.

will include the selected brand name in
its MCC submission currently planned
for late 2017.
HOPE, PROGRESS AND THE POWER OF PREVENTION
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MILE
STONE

Planning for future
milestones to expand
women’s options

“We need new prevention tools if we are to escape this
epidemic. Investment in research and development for new
prevention tools remains a critical goal for us all.”
– Naledi Pandor, minister of science and technology of South Africa

Any strategy to slow, and ultimately end, the epidemic must include a diverse preven-

IPM and MTN also planned for a Phase I trial of IPM’s

tion pipeline that addresses women’s comprehensive sexual and reproductive health

three-month dapivirine-contraceptive ring that is

needs. Using the dapivirine ring as a platform technology, IPM is steadily advancing a

designed to prevent HIV and unintended pregnancy, two

range of promising next-generation products that could offer women more effective

leading contributors to death and disability among women of

and convenient tools to protect their health.

reproductive age. Initiated in 2017, the trial is assessing the
ring’s safety and pharmacokinetics and includes the

In 2016, IPM and MTN prepared for a Phase I study of IPM’s three-month

three-month dapivirine-only ring for comparison. Results

dapivirine-only ring that would offer women longer-lasting protection. The study

from both Phase I studies will inform next steps for the

is planned for 2017 and will evaluate the safety and pharmacokinetics of rings with

dapivirine-contraceptive ring and help define the possible

different doses of dapivirine.

regulatory pathway for the three-month dapivirine-only ring.
Under agreements with leading pharmaceutical companies, IPM is also exploring products that

“HIV infection cannot be undone or reversed. The
ring can save their lives. The ring can give young
women back some power. The ring could become
an important arsenal in the fight against HIV among
young women, so I'll be keeping my eye and ear
close to its further development. The ring has in
me a new advocate!”
– Gqibelo Dandala, chief executive officer, Future of the African Daughter

would combine the potency of different ARVs with mechanisms of action that have not been used
for prevention. Introducing new routes of attack and disabling the virus in multiple ways in a single
product could help reduce the chance of acquiring drug-resistant HIV and improve the product’s
overall effectiveness.
Data analysis began in 2016 for a Phase I safety and tolerability trial of a vaginal tablet containing
DS003, a gp120 entry inhibitor licensed from Bristol-Myers Squibb. Results are expected in 2017
and will inform the development of a DS003-dapivirine vaginal ring. In addition, IPM is planning
analytical and preformulation studies of darunavir — a protease inhibitor licensed from Janssen
that is currently used for HIV treatment — to inform future prototypes of a darunavir-dapivirine
vaginal ring.
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IPM Donors
2016 Donors
Bill & Melinda Gates Foundation
Ministry of Foreign Affairs of Denmark
Flanders Department of Foreign Affairs
German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank
Irish Aid, Department of Foreign Affairs
Ministry of Foreign Affairs of the Netherlands through the Netherlands Enterprise Agency
Norwegian Agency for Development Cooperation, Norwegian Ministry of Foreign Affairs
United Kingdom Department for International Development
United States Agency for International Development through the United States President’s
Emergency Plan for AIDS Relief

Previous Donors
Ackerman Family Foundation
Belgian Development Cooperation
Canadian International Development Agency
European Commission
Federal Ministry for Economic Cooperation and Development, Germany
M•A•C AIDS Fund
Magee-Womens Research Institute and Foundation
Ministry for Foreign Affairs, Sweden
Ministry of Foreign Affairs and Cooperation, Spain
Ministry of Foreign Affairs, France
OPEC Fund for International Development, the development finance institution of OPEC
Member States
Rockefeller Foundation
Swedish International Development Agency
United Nations Population Fund
World Bank

2016 Board of Directors

2016 Scientific Advisory Board

James McIntyre, MBChB, Chair
Anova Health Institute, South Africa

Robin Shattock, PhD, Chair
Imperial College London, United Kingdom

Ayo Ajayi, MD, MPH
Bill & Melinda Gates Foundation, Ethiopia

David R. Friend, PhD
Evofem, United States

Pamela W. Barnes, MBA
Independent Consultant, United States

Sharon Hillier, PhD
Magee-Womens Hospital, University of
Pittsburgh School of Medicine, United States

Bruce Burlington, MD
Independent Consultant, United States
Georgina Caswell, MA
International HIV/AIDS Alliance, South Africa
Florence Houn, MD, MPH
Celgene Corporation, United States
Tamar Howson, MS, MBA
Independent Consultant, United States
Florence Manguyu, M.Med, MBChB
Aga Khan University Hospital; International AIDS
Vaccine Initiative, Kenya
Ndola Prata, MD, MSc
University of California, Berkeley School of Public
Health, United States
Zeda F. Rosenberg, ScD
IPM, United States
Michael Stevens
ENTHUSE Charitable Trust, United Kingdom

Ruth B. Merkatz, PhD, RN, FAAN
Population Council, United States
Thomas Moench, MD
ReProtect, Inc., United States
Derek Newall, PhD
Independent Consultant, United Kingdom
Doug Taylor, PhD
FHI 360, United States
Jim A. Turpin, PhD
National Institute of Allergy and Infectious
Diseases, National Institutes of Health,
United States
Lut Van Damme, PhD, MD
Bill & Melinda Gates Foundation, United States
Jens Van Roey, MD
Janssen Global Public Health, Belgium

Heidemarie Wieczorek-Zeul
Former Member of Parliament,
German Bundestag, Germany

IPM Leadership
Zeda F. Rosenberg, ScD
Founder and Chief Executive Officer

Mike Goldrich, MBA
President and Chief Operating Officer

Brid Devlin, PhD
Executive Vice President, Product Development

Patricia R. Mayer, PhD
Executive Vice President, Regulatory Affairs

Kathy Flynn, MBA
Chief Financial Officer

Annalene Nel, MD, PhD
Executive Vice President, Chief Medical Officer,
Clinical Programs
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2016 FINANCIAL
CONSIDERATIONS
IPM’s cash, cash equivalents and short-term investments as of Dec. 31, 2016,

In 2016, IPM received significant support from donors including the Ministry of Foreign

totaled USD 11.5 million. In 2016, IPM advanced three major programs:

Affairs of Denmark, the Flanders Department of Foreign Affairs, the German Federal

• Support to clinical research center partners and clinical activities to transition from
The Ring Study, one of two Phase III clinical trials of the dapivirine ring, to DREAM,
an open-label extension study that launched in July 2016 to provide the ring to
approximately 1,400 former Ring Study participants and 600 young women using
the product for the first time. Comprehensive analyses of Ring Study data continued in 2016. IPM also supported chemistry, manufacturing and control activities
to support the regulatory filing to the EMA, to automate some aspects of the ring
manufacturing process and scale up capacity in preparation for the ring’s potential
launch in African countries where women face high HIV risk.
• Regulatory activities to assemble a comprehensive dossier of data on the dapivirine ring and to prepare applications to license the ring that IPM currently plans to
submit in mid-2017 to the EMA, late 2017 to the MCC and in 2018 to the FDA.

erlands, Norad, DFID, USAID and the Bill & Melinda Gates Foundation. IPM received
approximately USD 29.7 million (cash receipts) in 2016.
IPM’s 2016 financial audits continue a history of full compliance with all financial reporting requirements from all US and international government and private donors. In 2016,
IPM again received unqualified, or clean, opinions on all audits in both its South Africa
and US offices.
IPM’s Board of Directors, management team and staff are committed to efficiently
and effectively deliver on our mission to accelerate the development and availability of
prevention products that women can use to protect against HIV infection. Women and
girls continue to become infected at alarming rates, especially in sub-Saharan Africa,

• Pipeline products, including the conduct and data analysis of the first clinical trial

and new products like the dapivirine ring have the potential to make a significant public

of DS003 and manufacturing of supplies for the first clinical trial of IPM’s three-

health impact. Sustained donor funding for IPM’s activities is essential, and we contin-

month dapivirine-contraceptive ring, which began in 2017. This work is conducted

ue to advocate for increased funds from existing donors and pursue new sources of

in consultation with IPM’s Scientific Advisory Board using a highly disciplined

support to achieve our goals.

approach to product prioritization that advances only the most promising self-initiated HIV prevention tools and other sexual and reproductive health technologies
for women.
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Statement of Financial Position

2016 Expenditures by Program
$33.8M

December 31, 2016
Assets

1%
4%

Phase III and IIIb Trials
(The Ring Study and DREAM)

11%

33%

Chemistry, Manufacturing &
Controls
Operations & Resource
Development

19%

Regulatory Preparations for Filing

16%

16%

Investments, at fair value

$5,194,090

Grants receivable

$4,823,974

Prepaid expenses and other assets
Property and equipment, net
Total Assets
Liabilities and net assets

Access

Liabilities

2016 Expenditures by Functional Category
$33.8M

Accounts payable and accrued expenses

$854,943
$2,875,959
$20,060,195

$4,130,315

Accrued payroll liabilities

$528,108

Grant advances and deferred revenue

$831,193

Deferred rent liability
Total Liabilities

$35,513
$5,525,129

Net assets

1%

12%
11%

$6,311,229

Product Pipeline

External Relations

2%

Cash and cash equivalents

External Contracts

Unrestricted net assets

$14,535,066

Total Liabilities and Net Assets

$20,060,195

Personnel

44%

Consulting Services
Other*

31%

Travel
Depreciation

*Includes rent, internet/phone, clinical trial insurance, legal fees, audit fees, regulatory fees and miscellaneous.
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IPM Headquarters
8405 Colesville Road
Suite 600
Silver Spring, MD 20910 USA
Tel: +1-301-608-2221
Fax: +1-301-608-2241

www.IPMglobal.org

IPM South Africa
63 Main Road
Paarl 7646, South Africa
P.O. Box 3460
Tel: +27-21-860-2300
Fax: +27-21-860-3208/1000

IPM Belgium AISBL
Square de Meeûs 38/40
B1000 Brussels
Belgium

Follow us on Twitter
at @IPMicrobicides

